- Home
- ILPT vs ASMB Comparison
ILPT vs ASMB Comparison
Compare ILPT & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILPT | ASMB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 574.7M | 512.1M |
| IPO Year | 2017 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ILPT | ASMB |
|---|---|---|
| Price | $8.35 | $33.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.05 | ★ $44.20 |
| AVG Volume (30 Days) | ★ 343.7K | 200.0K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | 31.51 | ★ 91.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $2.18 | $638.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.92 | $20.23 |
| 52 Week High | $9.43 | $39.71 |
Technical Indicators
Market Signals| Indicator | ILPT | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 40.02 | 68.22 |
| Support Level | $7.92 | $33.28 |
| Resistance Level | $9.29 | $34.69 |
| Average True Range (ATR) | 0.30 | 1.69 |
| MACD | -0.06 | 0.78 |
| Stochastic Oscillator | 13.18 | 89.39 |
Price Performance
Historical ComparisonAbout ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.